Comparison of 2-Weekly Versus 4-Weekly Durvalumab Consolidation for Locally Advanced NSCLC Treated With Chemoradiotherapy: A Brief Report

by Marie-Hélène Denault, MD, MSc, Shelley Kuang, MD, FRCPC, Aria Shokoohi, BSc, Bonnie Leung, MN-NP, Mitchell Liu, MDCM, FRCPC, Eric Berthelet, MD, FRCPC, Janessa Laskin, MD, FRCPC, Sophie Sun, MD, FRCPC, Tina Zhang, MD, FRCPC, Barbara Melosky, MD, FRCPC, Cheryl Ho, MD, FRCPC
Published 2022-05-01